A trial looking at crizotinib for breast and stomach cancer (ROLo)

This trial looked at crizotinib with fulvestrant for oestrogen receptor positive breast cancer. It also looked at crizotinib on its own for advanced triple negative breast cancer or stomach cancer.

The trial included people whose cancer had come back after treatment and either could not be removed with surgery, or it had spread to other parts of the body.

People could take part if they had 1 of the following:

• lobular breast cancer that was oestrogen receptor positive (ER positive) and HER2 negative (HER2 negative)

• triple negative lobular breast cancer

• diffuse stomach cancer that lacked a protein called E-cadherin

• other cancer types of cancer if they had a fault in a gene called CDH1 gene, which produces E-cadherin

People could join the trial between 2019 and 2023. The results were presented at a conference in 2024.